Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Fed. Circ.: Brand Pharmaceutical Company Entitled to 50% Of Generic Drug Maker's Profits During Patent Term Only
On April 7, 2015, a Federal Circuit panel of Judges O'Malley, Clevenger, and Bryson issued a unanimous opinion, authored by Judge Bryson, in Astrazeneca AB v. Apotex Corp., Case No. 2014-1221. The panel affirmed-in-part the district court's damages award to Astrazeneca AB (Astra) for 50% of Apotex's profits made during the patent term, but reversed Astra's damages award based on Apotex's profits made during the period of pediatric exclusivity, holding that 35 U.S.C. '284 only provides for reasonable royalty damages for patent infringement-based sales as opposed to sales made after a patent expires. See, Slip op. at 31'35.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.